Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests

Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests
Detection of specific genetic alterations and immunological biomarkers can help predict the response to QBECO SSI immunotherapy in patients with inflammatory bowel disease (IBD). This finding resulted from the analysis of Phase 2 trial data in ulcerative colitis. QBECO SSI therapy was developed by Qu Biologics based on the company’s Site Specific Immunomodulators (SSIs) platform. This investigative immunotherapy was derived from inactivated components of E. coli bacteria in order to restore the innate immune response in the host’s gastrointestinal tract. Compared to currently available immunotherapies, QBECO SSI does not inhibit the immune system, but reinitiates the normal immune function while clearing what triggers the disease. Results from a QBECO SSIs Phase 2 trial (NCT02426372) in patients with moderate to severe ulcerative colitis showed 73% of patients who received the treatment achieved a meaningful clinical response, and 45% presented endoscopic healing within the first 16 weeks of treatment. “For patients with IBD, including ulcerative colitis and Crohn’s disease, we are hopeful that these results mean that they may now be closer to having a treatment that restores rather than suppresses immune function," Dr. Hal Gunn, CEO of Qu Biologics, said in a press releas
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *